

Drug resistance interpretation: PR	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

PI Major Mutations:	None
PI Accessory Mutations:	None
PR Other Mutations:	I13V ^{98%} _{pos=3,382} • G16A ^{95%} _{pos=8,836} • E35D ^{95%} _{pos=7,333} • M36I ^{95%} _{pos=7,375} • R41K ^{95%} _{pos=7,887} • R57K ^{95%} _{pos=8,552} • L63P ^{94%} _{pos=8,875} • H69K ^{93%} _{pos=8,085} • L89M ^{93%} _{pos=8,281}
Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

NRTI Mutations:	None
NNRTI Mutations:	G190A ^{97%} _{pos=1,898}
RT Other Mutations:	V35T ^{95%} _{pos=1,2763} • T39E ^{94%} _{pos=1,712} • K102N ^{94%} _{pos=1,302} • D121H ^{93%} _{pos=1,096} • K122E ^{94%} _{pos=1,096} • I142V ^{94%} _{pos=1,038} • Q145C ^{94%} _{pos=1,137} • D177E ^{94%} _{pos=1,864} • Q197K ^{94%} _{pos=1,817} • Q207E ^{94%} _{pos=1,261} • R211K ^{94%} _{pos=1,230} • V245K ^{94%} _{pos=1,007} • T286A ^{94%} _{pos=208} • E291D ^{94%} _{pos=1,279} • V292I ^{93%} _{pos=1,279} • I293V ^{93%} _{pos=1,279} • E297K ^{93%} _{pos=180} • A304E ^{94%} _{pos=1,112} • E312D ^{94%} _{pos=79} • K512KR ^{94-95%} _{pos=1,368} • S519N ^{94%} _{pos=1,338} • Q524QK ^{94-95%} _{pos=1,336} • Q527KE ^{94-95%} _{pos=1,717} • A534S ^{94%} _{pos=1,828} • A554N ^{93%} _{pos=1,262}
Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible
Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	Susceptible
efavirenz (EFV)	Intermediate Resistance
etravirine (ETR)	Potential Low-Level Resistance
nevirapine (NVP)	High-Level Resistance
rilpivirine (RPV)	Low-Level Resistance

RT comments
NNRTI
<ul style="list-style-type: none">G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR.This virus is predicted to have low-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be relatively contraindicated.

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:

[Download CSV](#)

Rule	DOR	EFV	ETR	NVP	RPV
G190A	0	45	10	60	15

Drug resistance interpretation: IN	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

INSTI Major Mutations:	None
INSTI Accessory Mutations:	None
IN Other Mutations:	S245H ^{94-95%} _{pos=1,332} • K42KR ^{94-95%} _{pos=1,329} • L101I ^{95%} _{pos=1,017} • T112V ^{94%} _{pos=1,529} • S119G ^{94%} _{pos=1,879} • T122I ^{94%} _{pos=1,761} • T124A ^{94%} _{pos=1,626} • T125A ^{93%} _{pos=1,621} • G134D ^{94%} _{pos=1,863} • K136Q ^{94%} _{pos=1,319} • V201I ^{93%} _{pos=1,876} • L234I ^{93%} _{pos=4,870} • S283G ^{94%} _{pos=1,857}
Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

Mutation scoring: IN	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for INSTI.